Grey Wolf Therapeutics Revenue and Competitors

Milton, Oxfordshire

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Grey Wolf Therapeutics's estimated annual revenue is currently $2.9M per year.(i)
  • Grey Wolf Therapeutics's estimated revenue per employee is $77,500

Employee Data

  • Grey Wolf Therapeutics has 37 Employees.(i)
  • Grey Wolf Therapeutics grew their employee count by 42% last year.

Grey Wolf Therapeutics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.2M1550%N/AN/A
#2
$0.3M40%N/AN/A
#3
$0.9M110%N/AN/A
#4
$2.9M3742%N/AN/A
Add Company

What Is Grey Wolf Therapeutics?

Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cells, illuminating them for attack and destruction by the immune system. We are targeting a key protein in the antigen presentation pathway to drive modulation of the neoantigen repertoire on tumour cells, thus dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology. Grey Wolf is working with leading academic and commercial drug discovery partners to deliver a clinical candidate against a strongly validated target. The Grey Wolf team is made up of experts in immuno-oncology, antigen presentation and drug discovery. For more information, visit the website or email enquiries@gwt.bio.

keywords:N/A

N/A

Total Funding

37

Number of Employees

$2.9M

Revenue (est)

42%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.7M389%N/A
#2
$8.8M3819%N/A
#3
$35M395%N/A
#4
$4.6M4021%N/A
#5
$9.1M425%N/A